---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-24-000025"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:53:49.735855+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Exelixis Q4 2023 revenue $479.7M, GAAP EPS $0.27, non-GAAP $0.33; FY revenue $1.83B

## Summary
- Total Q4 revenues $479.7M (up from $423.9M YoY); cabozantinib net product revenues $429.3M.
- GAAP diluted EPS $0.27 (Q4) and $0.65 (FY); non-GAAP diluted EPS $0.33 (Q4) and $0.90 (FY).
- FY 2023 total revenues $1.83B, up 14% from $1.61B; net product revenues $1.63B.
- R&D expenses $244.7M (Q4) vs $336.8M YoY; SG&A $131.4M vs $119.3M YoY.
- Pipeline: regulatory strategies for cabozantinib label expansions; MSN IP litigation ruling expected spring 2024.

## SEC filing metadata
- accession: 0000939767-24-000025
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976724000025/0000939767-24-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976724000025/exel-20240206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-24-000025
- JSON: https://secwatch.observer/filing/0000939767-24-000025.json
- Plain text: https://secwatch.observer/filing/0000939767-24-000025.txt

## Key facts
- Earnings Releases
  EXELIXIS, INC. reported financial results for quarter and year ended December 31, 2023.
  - Period: quarter and year ended December 31, 2023
  - Result: reported results
  source text: On February 6, 2024, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter and full year ended December 29, 2023, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/939767/000093976724000025/0000939767-24-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.